A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer.

@article{Voest2011ART,
  title={A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer.},
  author={E E Voest and Nikol Snoeren and Sander B. Schouten and Andries M. Bergman and Erik D van Werkhoven and Olaf J L Loosveld and Thomas Matthijs van Gulik and J M Smit and Annemieke Cats and Epie Boven and Erik J Hesselink and Arjen M. Rijken and Marc J. Tol and Otilia B Dalesio and Henk M. W. Verheul and Rob A. E. M. Tollenaar and Joost R M M van der Sijp and I. H. M. Borel Rinkes and Richard van Hillegersberg},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={3565}
}
3565 Background: This study aimed to improve disease-free survival (DFS) for patients after radical resection of CRC liver metastases by adding bevacizumab to post resection chemotherapy with CAPOX. METHODS Patients with liver only disease who underwent a radical (R0) resection of liver metastases of CRC cancer were randomized between CAPOX (arm A) or the same schedule plus bevacizumab 7.5 mg/kg i.v. day 1 (arm B). CAPOX was given for a total of 8 cycles whereas bevacizumab was given for 12… CONTINUE READING

Similar Papers

Loading similar papers…